Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Treatment options for the eradication of intestinal protozoa

Abstract

Pathogenic intestinal protozoa are responsible for clinically important infections in both the developed and the developing world. These organisms are responsible for both acute and chronic diarrhea, and Entamoeba histolytica, which affects the colon, can spread to involve the liver. Many of these pathogens, particularly the intracellular protozoa that predominantly affect the small intestine, produce their most devastating effects in patients with HIV/AIDS and other forms of immune deficiency. There are also various intestinal protozoa that do not seem to have any adverse effects on humans and can, therefore, be regarded as harmless commensal organisms. Although treatment has been available for several decades for giardiasis, isosporiasis and amoebiasis, until recently there have been no effective remedies for infection with intestinal coccidia—Cryptosporidium, Microsporidium and Cyclospora species. Cyclospora respond well to co-trimoxazole, microsporidia respond variably to albendazole, and cryptosporidia can often be eradicated by nitazoxanide. In chronically infected HIV-positive patients, treatment with multidrug regimens usually results in rapid resolution of the diarrhea and, in many instances, eradication of the parasite.

Key Points

  • Intestinal protozoa cause clinically significant infections in both the developed and developing worlds, particularly in individuals with impaired cell-mediated immunity

  • The clinical impact of infection with intracellular intestinal protozoa (Cryptosporidium, Microsporidia, Cyclospora, Isospora) in HIV-positive patients has been dramatically reduced following the introduction of highly active antiretroviral therapy (i.e. triple drug regimens)

  • Cryptosporidiosis was a major clinical challenge, but can now be effectively treated with nitazoxanide (a substituted benzamide); treatment with nitazoxanide is also effective and safe in children

  • Infection with the relatively new pathogen Cyclospora (like Isospora infection) can be cleared with co-trimoxazole

  • Microsporidiosis remains a therapeutic challenge, but clinical trials indicate that albendazole and fumagillin are effective therapeutic options, although clearance is not consistently achieved

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Farthing MJG (1989) Host–parasite interactions in human giardiasis. Q J Med 70: 191–204

    CAS  PubMed  Google Scholar 

  2. Adam RD (1991) The biology of Giardia spp. Microbiol Rev 55: 706–732

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Farthing MJG (1993) Giardiasis as a disease. In Giardia: From Molecules to Disease and Beyond. 15–37 (eds JA Reynoldson et al.) London: CAB International

    Google Scholar 

  4. Davidson RA (1984) Issues in clinical parasitology: the treatment of giardiasis. Am J Gastroenterol 79: 256–261

    CAS  PubMed  Google Scholar 

  5. Crouch AA et al. (1986) Effect of twenty-three chemotherapeutic agents on the adherence and growth of Giardia lamblia in vitro. Trans R Soc Trop Med Hyg 80: 893–896

    CAS  PubMed  Google Scholar 

  6. Abboud P et al. (2001) Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 32: 1792–1794

    CAS  PubMed  Google Scholar 

  7. Butcher PD et al. (1994) Phenotypic and genotypic variation in Giardia lamblia isolates during chronic infection. Gut 35: 51–54

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Gardner TB and Hill DR (2001) Treatment of giardiasis. Clin Microbiol Rev 14: 114–128

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Zaat JO et al. (2000) Drugs for treating giardiasis. The Cochrane Database of Systematic Reviews, Issue 2, Art. No CD000217

    Google Scholar 

  10. Boreham PFL (1992) Current status of chemotherapy for giardiasis. In Giardia: From Molecules to Disease. 317–328 (Eds RCA Thompson et al.) Oxford: CAB International

    Google Scholar 

  11. Ortiz JJ et al. (2001) Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Aliment Pharmacol Ther 15: 1409–1415

    CAS  PubMed  Google Scholar 

  12. Rossignol JF et al. (2002) Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 184: 381–384

    Google Scholar 

  13. Bailey JM and Erramouspe J (2004) Nitazoxanide treatment for giardiasis and cryptosporidiosis in children. Ann Pharmacother 38: 634–640

    CAS  PubMed  Google Scholar 

  14. Anderson KA et al. (2004) Impact of Giardia vaccination on asymptomatic Giardia infections in dogs at a research facility. Can Vet J 45: 924–930

    PubMed  PubMed Central  Google Scholar 

  15. Olson ME et al. (2000) Giardia vaccination. Parasitol Today 16: 213–217

    CAS  PubMed  Google Scholar 

  16. Stein JE et al. (2003) Efficacy of Giardia vaccination in the treatment of giardiasis in cats. J Am Vet Med Assoc 222: 1548–1551

    PubMed  Google Scholar 

  17. Nime FA et al. (1976) Acute enterocolitis in a human being infected with the protozoan Cryptosporidium. Gastroenterology 70: 592–598

    CAS  PubMed  Google Scholar 

  18. Current WL and Bick PH (1989) Immunobiology of Cryptosporidium spp. Pathol Immunopathol Res 8: 141–160

    CAS  PubMed  Google Scholar 

  19. Farthing MJG (2000) Clinical aspects of human cryptosporidiosis. In Cryptosporidiosis and microsporidiosis. (Eds Petry F and Karger B) Contrib Microbiol 6: 50–74

    Google Scholar 

  20. Teixidor HS et al. (1991) Cryptosporidiosis of the biliary tract in AIDS. Radiology 180: 51–56

    CAS  PubMed  Google Scholar 

  21. Ochiai Y et al. (2005) Detection and discrimination of Cryptosporidium parvum and C. hominis in water samples by immunomagnetic separation-PCR. Appl Environ Microbiol 71: 898–903

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Baishanbo A et al. (2005) Infectivity of Cryptosporidium hominis and Cryptosporidium parvum genotype 2 isolates in immunosuppressed Mongolian gerbils. Infect Immun 73: 5252–5255

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Schindler AR et al. (2005) Capillary electrophoretic analysis of fragment length polymorphisms in ribosomal markers of Cryptosporidium from humans. Mol Cell Probes 19: 394–399

    CAS  PubMed  Google Scholar 

  24. Carr A et al. (1998) Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 351: 256–261

    CAS  PubMed  Google Scholar 

  25. Foudraine NA et al. (1998) Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy. AIDS 1: 35–41

    Google Scholar 

  26. Le Moing V et al. (1998) Decreased prevalence of intestinal cryptosporidiosis in HIV-infected patients concomitant to the widespread use of protease inhibitors. AIDS 12: 1395–1397

    CAS  PubMed  Google Scholar 

  27. Clezy K et al. (1991) Paromomycin for the treatment of cryptosporidial diarrhoea in AIDS patients. AIDS 5: 1146–1147

    CAS  PubMed  Google Scholar 

  28. Fichtenbaum CJ et al. (1993) Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS. Clin Infect Dis 16: 298–300

    CAS  PubMed  Google Scholar 

  29. Hoepelman AI (1996) Current therapeutic approaches to cryptosporidiosis in immunocompromised patients. J Antimicrob Chemother 37: 871–880

    CAS  PubMed  Google Scholar 

  30. Doumbo O et al. (1997) Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am J Trop Med Hyg 56: 637–639

    CAS  PubMed  Google Scholar 

  31. Rossignol JF et al. (1998) A double-blind placebo controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Med 92: 663–666

    CAS  Google Scholar 

  32. Rossignol JF et al. (2001) Treatment of diarrhea caused by Cryptosporidium parvum: a prospective, randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 184: 103–106

    CAS  PubMed  Google Scholar 

  33. Amadi B et al. (2002) Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomized controlled trial. Lancet 360: 1375–1380

    PubMed  Google Scholar 

  34. Zulu I et al. (2005) Nitazoxanide for persistent diarrhoea in Zambian acquired immune deficiency syndrome patients: a randomized controlled trial. Aliment Pharmacol Ther 21: 757–763

    CAS  PubMed  Google Scholar 

  35. Portnoy D et al. (1984) Treatment of intestinal cryptosporidiosis with spiramycin. Ann Intern Med 101: 202–204

    CAS  PubMed  Google Scholar 

  36. Saez-Llorens X (1989) Spiramycin for treatment of Cryptosporidium enteritis. J Infect Dis 160: 342

    CAS  PubMed  Google Scholar 

  37. Wittenberg DF et al. (1989) Spiramycin is not effective in treating Cryptosporidium diarrhea in infants: results of a double-blind randomized trial. J Infect Dis 159: 131–132

    CAS  PubMed  Google Scholar 

  38. Dionisio D et al. (1998) Chronic cryptosporidiosis in patients with AIDS: stable remission and possible eradication after long-term, low dose azithromycin. J Clin Pathol 51: 138–142

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Uip DE et al. (1998) Roxithromycin treatment of diarrhoea caused by Cryptosporidium spp. in patients with AIDS. J Antimicrob Chemother 41: 93–97

    CAS  PubMed  Google Scholar 

  40. Sprinz E et al. (1998) AIDS-related cryptosporidial diarrhoea: an open study with roxithromycin. J Antimicrob Chemother 41: 85–91

    CAS  PubMed  Google Scholar 

  41. Kelly P et al. (1996) Albendazole chemotherapy for treatment of diarrhoea in patients with AIDS in Zambia: a randomised double-blind controlled trial. Br Med J 312: 1187–1191

    CAS  Google Scholar 

  42. Kelly MP et al. (1998) Eradication of intracellular protozoa in AIDS patients using high dose albendazole [abstract]. Gastroenterology 114: A1007

    Google Scholar 

  43. Tzipori S et al. (1986) Remission of diarrhoea due to cryptosporidiosis in an immunodeficient child treated with hyperimmune bovine colostrum. Br Med J 293: 1276–1277

    CAS  Google Scholar 

  44. Tzipori S et al. (1987) Chronic cryptosporidial diarrhoea and hyperimmune cow colostrum. Lancet 2: 344–345

    CAS  PubMed  Google Scholar 

  45. Ungar BLP et al. (1990) Cessation of Cryptosporidium-associated diarrhea in an acquired immunodeficiency syndrome patient after treatment with hyperimmune bovine colostrum. Gastroenterology 98: 486–489

    CAS  PubMed  Google Scholar 

  46. Greenberg PD and Cello JP (1996) Treatment of severe diarrhea caused by Cryptosporidium parvum with oral bovine immunoglobulin concentrate in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 13: 348–354

    CAS  PubMed  Google Scholar 

  47. McMeeking A et al. (1990) A controlled trial of bovine dialysable leukocyte extract for cryptosporidiosis in patients with AIDS. J Infect Dis 161: 108–112

    CAS  PubMed  Google Scholar 

  48. De Hovitz JA et al. (1986) Clinical manifestations and therapy of Isospora belli infection in patients with AIDS. N Engl J Med 315: 87–90

    CAS  Google Scholar 

  49. Trier JS et al. (1974) Chronic intestinal coccidiosis in man: intestinal pathology and response to treatment. Gastroenterology 66: 923–935

    CAS  PubMed  Google Scholar 

  50. Pape JW et al. (1989) Treatment and prophylaxis of Isospora belli infections in patients with AIDS. N Engl J Med 320: 1044–1047

    CAS  PubMed  Google Scholar 

  51. Sturchler D (1987) Parasitic diseases of the small intestinal tract. Baillieres Clin Gastroenterol 1: 397–424

    CAS  PubMed  Google Scholar 

  52. Shlim DR et al. (1991) An algae-like organism associated with an outbreak of prolonged diarrhea among foreigners in Nepal. Am J Trop Med Hyg 45: 383–389

    CAS  PubMed  Google Scholar 

  53. Ortega YR et al. (1993) Cyclospora species—a new protozoan pathogen of humans. N Engl J Med 328: 1308–1312

    CAS  PubMed  Google Scholar 

  54. Hoge CW et al. (1993) Epidemiology of diarrhoeal illness associated with coccidian-like organism among travellers and foreign residents in Nepal. Lancet 341: 1175–1179

    CAS  PubMed  Google Scholar 

  55. Hoge CW et al. (1995) Placebo-controlled trial of co-trimoxazole for Cyclospora infections among travellers and foreign residents in Nepal. Lancet 345: 691–693

    CAS  PubMed  Google Scholar 

  56. Verdier RI et al. (2000) Trimethoprim–sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med 132: 885–888

    CAS  PubMed  Google Scholar 

  57. Modigliani R et al. (1985) Diarrhoea and malabsorption in AIDS: a study of four cases with special emphasis on opportunistic protozoan infections. Gut 26: 179–187

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Orenstein JM et al. (1992) Localization of infection by the microsporidian Enterocytozoon bieneusi in the gastrointestinal tract of AIDS patients with diarrhoea. AIDS 6: 195–197

    CAS  PubMed  Google Scholar 

  59. Blanshard C et al. (1992) Treatment of intestinal microsporidiosis with albendazole in patients with AIDS. AIDS 6: 311–313

    CAS  PubMed  Google Scholar 

  60. Conteas CN et al. (2000) Therapy for human gastrointestinal microsporidiosis. Am J Trop Med Hyg 63: 121–127

    CAS  PubMed  Google Scholar 

  61. Tremoulet AH et al. (2004) Albendazole therapy for Microsporidium diarrhea in immunocompetent Costa Rican children. Pediatr Infect Dis J 23: 915–918

    PubMed  Google Scholar 

  62. Molina JM et al. (2002) Fumagillin treatment of intestinal microsporidiosis. N Engl J Med 346: 1963–1969

    CAS  PubMed  Google Scholar 

  63. Cali A et al. (1993) Septata intestinalis N. G., N. sp., an intestinal microsporidian associated with chronic diarrhoea and dissemination in AIDS patients. J Eukaryot Microbiol 40: 101–112

    CAS  PubMed  Google Scholar 

  64. Walsh JA (1986) Problems in recognition and diagnosis of amebiasis: estimation of the global magnitude of morbidity and mortality. Rev Infect Dis 8: 228–252

    CAS  PubMed  Google Scholar 

  65. Stauffer W and Ravdin JI (2003) Entamoeba histolytica: an update. Curr Opin Infect Dis 16: 479–485

    PubMed  Google Scholar 

  66. Gathiram V and Jackson TF (1987) A longitudinal study of asymptomatic carriers of pathogenic zymodemes of Entamoeba histolytica. S Afr Med J 72: 669–672

    CAS  PubMed  Google Scholar 

  67. Li E and Stanley SL (1996) Amebiasis. Gastroenterol Clin North Am 25: 471–492

    CAS  PubMed  Google Scholar 

  68. Stanley SL (2004) Antiparasitic agents. In Infectious diseases, Edn 2 1941–1960 (Eds Cohen J and Powderly WG). Edinburgh: Mosby

    Google Scholar 

  69. Arean VM and Koppisch E (1956) Balantidiasis: a review and report of cases. Am J Pathol 32: 1089–1115

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Samranwetaya P et al. (1972) Fatal balantidial colitis. Report of a case. J Med Assoc Thai 55: 259–262

    CAS  PubMed  Google Scholar 

  71. Garcia-Laverde A and De Bonilla L (1975) Clinical trials with metronidazole in human balantidiasis. Am J Trop Med Hyg 24: 781–783

    CAS  PubMed  Google Scholar 

  72. Stenzel DJ and Boreham PFL (1996) Blastocystis hominis revisited. Clin Microbiol Rev 9: 563–584

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Leder K et al. (2005) No correlation between clinical symptoms and Blastocystis hominis in immunocompetent individuals. J Gastroenterol Hepatol 20: 1390–1394

    PubMed  Google Scholar 

  74. Schlim DR et al. (1995) Is Blastocystis a cause of diarrhea in travelers? A prospective controlled study in Nepal. Clin Infect Dis 21: 97–101

    Google Scholar 

  75. Jellinek T et al. (1997) The role of Blastocystis hominis as a possible intestinal pathogen in travellers. J Infect 35: 63–66

    Google Scholar 

  76. Amenta M et al. (1999) Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections. J Chemother 11: 391–395

    CAS  PubMed  Google Scholar 

  77. Moghaddam DD et al. (2005) Blastocystis hominis and the evaluation of efficacy of metronidazole and trimethoprim/sulfamethoxazole. Parasitol Res 96: 273–275

    PubMed  Google Scholar 

  78. Ok UZ et al. (1999) Effect of trimethoprim/sulfamethoxazole in Blastocystis hominis infection. Am J Gastroenterol 94: 3245–3247

    CAS  PubMed  Google Scholar 

  79. Rossignol JF et al. (2005) Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis. Clin Gastroenterol Hepatol 3: 987–991

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael JG Farthing.

Ethics declarations

Competing interests

The author has been involved in clinical trials of albendazole and nitazoxanide, and has received research funding for these trials from SmithKline Beecham Pharmaceuticals and Romark Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Farthing, M. Treatment options for the eradication of intestinal protozoa. Nat Rev Gastroenterol Hepatol 3, 436–445 (2006). https://doi.org/10.1038/ncpgasthep0557

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0557

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing